Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Correction to: A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice.

Liu GS, Ballweg R, Ashbaugh A, Zhang Y, Facciolo J, Cushion MT, Zhang T.

BMC Syst Biol. 2019 Aug 12;13(1):40. doi: 10.1186/s12918-019-0708-9.

2.

Expression and Immunostaining Analyses Suggest that Pneumocystis Primary Homothallism Involves Trophic Cells Displaying Both Plus and Minus Pheromone Receptors.

Luraschi A, Richard S, Almeida JMGCF, Pagni M, Cushion MT, Hauser PM.

MBio. 2019 Jul 9;10(4). pii: e01145-19. doi: 10.1128/mBio.01145-19.

3.

Magnesium, calcium and zinc [N2N'] heteroscorpionate complexes.

Luna Barros M, Cushion MG, Schwarz AD, Turner ZR, Mountford P.

Dalton Trans. 2019 Mar 26;48(13):4124-4138. doi: 10.1039/c8dt04985h.

PMID:
30638242
4.

Is sex necessary for the proliferation and transmission of Pneumocystis?

Hauser PM, Cushion MT.

PLoS Pathog. 2018 Dec 6;14(12):e1007409. doi: 10.1371/journal.ppat.1007409. eCollection 2018 Dec. Review. No abstract available.

5.

Correction: Development of highly active anti-Pneumocystis bisbenzamidines: insight into the influence of selected substituents on the in vitro activity.

Maciejewska D, Żabiński J, Rezler M, Kaźmierczak P, Collins MS, Ficker L, Cushion MT.

Medchemcomm. 2017 Nov 7;8(11):2164. doi: 10.1039/c7md90042b. eCollection 2017 Nov 1.

6.

Chloroquine Analogues as Leads against Pneumocystis Lung Pathogens.

Gomes A, Ferraz R, Ficker L, Collins MS, Prudêncio C, Cushion MT, Teixeira C, Gomes P.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e00983-18. doi: 10.1128/AAC.00983-18. Print 2018 Nov.

7.

Development of highly active anti-Pneumocystis bisbenzamidines: insight into the influence of selected substituents on the in vitro activity.

Maciejewska D, Żabiński J, Rezler M, Kaźmierczak P, Collins MS, Ficker L, Cushion MT.

Medchemcomm. 2017 Oct 5;8(10):2003-2011. doi: 10.1039/c7md00445a. eCollection 2017 Oct 1. Erratum in: Medchemcomm. 2017 Nov 7;8(11):2164.

8.

Reply to Nevez et al., "The Fascinating Echinocandin-Treated Mouse Model of Pneumocystis murina To Understand Pneumocystis jirovecii".

Cushion MT.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e01036-18. doi: 10.1128/AAC.01036-18. Print 2018 Aug. No abstract available.

9.

A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice.

Liu GS, Ballweg R, Ashbaugh A, Zhang Y, Facciolo J, Cushion MT, Zhang T.

BMC Syst Biol. 2018 Jul 17;12(1):77. doi: 10.1186/s12918-018-0603-9. Erratum in: BMC Syst Biol. 2019 Aug 12;13(1):40.

10.

The 14th International Workshops on Opportunistic Protists (IWOP 14).

Cushion MT, Limper AH, Porollo A, Saper VE, Sinai AP, Weiss LM.

J Eukaryot Microbiol. 2018 Nov;65(6):934-939. doi: 10.1111/jeu.12631. Epub 2018 May 25.

11.

Erratum for Mor et al., "Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids".

Mor V, Rella A, Farnoud AM, Singh A, Munshi M, Bryan A, Naseem S, Konopka JB, Ojima I, Bullesbach E, Ashbaugh A, Linke MJ, Cushion M, Collins M, Ananthula HK, Sallans L, Desai PB, Wiederhold NP, Fothergill AW, Kirkpatrick WR, Patterson T, Wong LH, Sinha S, Giaever G, Nislow C, Flaherty P, Pan X, Cesar GV, de Melo Tavares P, Frases S, Miranda K, Rodrigues ML, Luberto C, Nimrichter L, Del Poeta M.

MBio. 2018 Mar 13;9(2). pii: e00188-18. doi: 10.1128/mBio.00188-18. No abstract available.

12.

Acylhydrazones as Antifungal Agents Targeting the Synthesis of Fungal Sphingolipids.

Lazzarini C, Haranahalli K, Rieger R, Ananthula HK, Desai PB, Ashbaugh A, Linke MJ, Cushion MT, Ruzsicska B, Haley J, Ojima I, Del Poeta M.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00156-18. doi: 10.1128/AAC.00156-18. Print 2018 May.

13.

Gene Expression of Pneumocystis murina after Treatment with Anidulafungin Results in Strong Signals for Sexual Reproduction, Cell Wall Integrity, and Cell Cycle Arrest, Indicating a Requirement for Ascus Formation for Proliferation.

Cushion MT, Ashbaugh A, Hendrix K, Linke MJ, Tisdale N, Sayson SG, Porollo A.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02513-17. doi: 10.1128/AAC.02513-17. Print 2018 May.

14.

A Quantitative Model to Estimate Drug Resistance in Pathogens.

Baker FN, Cushion MT, Porollo A.

J Fungi (Basel). 2016 Dec;2(4). pii: 30. doi: 10.3390/jof2040030. Epub 2016 Dec 5.

15.

Functional Characterization of Pneumocystis carinii Inositol Transporter 1.

Cushion MT, Collins MS, Sesterhenn T, Porollo A, Vadukoot AK, Merino EJ.

MBio. 2016 Dec 13;7(6). pii: e01851-16. doi: 10.1128/mBio.01851-16.

16.

The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.

Koselny K, Green J, DiDone L, Halterman JP, Fothergill AW, Wiederhold NP, Patterson TF, Cushion MT, Rappelye C, Wellington M, Krysan DJ.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7115-7127. Print 2016 Dec.

17.

Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids.

Mor V, Rella A, Farnoud AM, Singh A, Munshi M, Bryan A, Naseem S, Konopka JB, Ojima I, Bullesbach E, Ashbaugh A, Linke MJ, Cushion M, Collins M, Ananthula HK, Sallans L, Desai PB, Wiederhold NP, Fothergill AW, Kirkpatrick WR, Patterson T, Wong LH, Sinha S, Giaever G, Nislow C, Flaherty P, Pan X, Cesar GV, de Melo Tavares P, Frases S, Miranda K, Rodrigues ML, Luberto C, Nimrichter L, Del Poeta M.

MBio. 2015 Jun 23;6(3):e00647. doi: 10.1128/mBio.00647-15. Erratum in: MBio. 2018 Mar 13;9(2):.

18.

The 13th International Workshops on Opportunistic Protists (IWOP13).

Calderon EJ, Cushion MT, Xiao L, Lorenzo-Morales J, Matos O, Kaneshiro ES, Weiss LM.

J Eukaryot Microbiol. 2015 Sep-Oct;62(5):701-9. doi: 10.1111/jeu.12221. Epub 2015 May 28.

19.

Comparative genomics of pneumocystis species suggests the absence of genes for myo-inositol synthesis and reliance on inositol transport and metabolism.

Porollo A, Sesterhenn TM, Collins MS, Welge JA, Cushion MT.

MBio. 2014 Nov 4;5(6):e01834. doi: 10.1128/mBio.01834-14.

20.

Comparison of analytical sensitivity and women's interpretation of home pregnancy tests.

Johnson S, Cushion M, Bond S, Godbert S, Pike J.

Clin Chem Lab Med. 2015 Feb;53(3):391-402. doi: 10.1515/cclm-2014-0643.

PMID:
25274958
21.

Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice.

Lobo ML, Esteves F, de Sousa B, Cardoso F, Cushion MT, Antunes F, Matos O.

PLoS One. 2013 Aug 5;8(8):e70619. doi: 10.1371/journal.pone.0070619. Print 2013.

22.

Assembly and annotation of Pneumocystis jirovecii from the human lung microbiome.

Cushion MT, Keely SP.

MBio. 2013 Apr 16;4(2):e00224. doi: 10.1128/mBio.00224-13.

23.

The 12th International Workshops on Opportunistic Protists (IWOP-12).

Weiss LM, Cushion MT, Didier E, Xiao L, Marciano-Cabral F, Sinai AP, Matos O, Calderon EJ, Kaneshiro ES.

J Eukaryot Microbiol. 2013 May-Jun;60(3):298-308. doi: 10.1111/jeu.12034. Epub 2013 Apr 5.

24.

Characterization of a distinct host response profile to Pneumocystis murina asci during clearance of pneumocystis pneumonia.

Linke MJ, Ashbaugh A, Collins MS, Lynch K, Cushion MT.

Infect Immun. 2013 Mar;81(3):984-95. doi: 10.1128/IAI.01181-12. Epub 2013 Jan 14.

25.

Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome.

Porollo A, Meller J, Joshi Y, Jaiswal V, Smulian AG, Cushion MT.

Curr Drug Targets. 2012 Nov;13(12):1575-85. Review.

26.

Analogs of pentamidine as potential anti-Pneumocystis chemotherapeutics.

Maciejewska D, Zabinski J, Kaźmierczak P, Rezler M, Krassowska-Świebocka B, Collins MS, Cushion MT.

Eur J Med Chem. 2012 Feb;48:164-73. doi: 10.1016/j.ejmech.2011.12.010. Epub 2011 Dec 13.

27.

The state of research for AIDS-associated opportunistic infections and the importance of sustaining smaller research communities.

Sinai AP, Kaneshiro ES, Ward H, Weiss LM, Cushion MT.

Eukaryot Cell. 2012 Feb;11(2):90-7. doi: 10.1128/EC.05143-11. Epub 2011 Dec 9. No abstract available.

28.

Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures.

Cushion MT, Collins MS.

Antimicrob Agents Chemother. 2011 Oct;55(10):4513-8. doi: 10.1128/AAC.00017-11. Epub 2011 Jul 25.

29.

Cationic and charge-neutral calcium tetrahydroborate complexes and their use in the controlled ring-opening polymerisation of rac-lactide.

Cushion MG, Mountford P.

Chem Commun (Camb). 2011 Feb 28;47(8):2276-8. doi: 10.1039/c0cc04348f. Epub 2010 Dec 17.

PMID:
21165502
30.

Highlights and summaries of the 11th International Workshops on Opportunistic Protists.

Kaneshiro ES, Cushion MT, Marciano-Cabral F, Weiss LM, Xiao L.

J Eukaryot Microbiol. 2011 Jan-Feb;58(1):1-6. doi: 10.1111/j.1550-7408.2010.00515.x. Epub 2010 Dec 3.

31.

Cu(I) complexes based on cis, cis-1,3,5-tris(arylideneamino)cyclohexane ligands: synthesis, structure and CO binding.

Ebrahimpour P, Cushion M, Haddow MF, Hallett AJ, Wass DF.

Dalton Trans. 2010 Dec 7;39(45):10910-9. doi: 10.1039/c0dt00986e. Epub 2010 Oct 21.

PMID:
20967334
32.

Are members of the fungal genus pneumocystis (a) commensals; (b) opportunists; (c) pathogens; or (d) all of the above?

Cushion MT.

PLoS Pathog. 2010 Sep 23;6(9):e1001009. doi: 10.1371/journal.ppat.1001009. No abstract available.

33.

Sterol biosynthesis and sterol uptake in the fungal pathogen Pneumocystis carinii.

Joffrion TM, Cushion MT.

FEMS Microbiol Lett. 2010 Oct;311(1):1-9. doi: 10.1111/j.1574-6968.2010.02007.x. Review.

34.

Stealth and opportunism: alternative lifestyles of species in the fungal genus Pneumocystis.

Cushion MT, Stringer JR.

Annu Rev Microbiol. 2010;64:431-52. doi: 10.1146/annurev.micro.112408.134335. Review.

PMID:
20528694
35.

Synthesis and ethylene trimerisation capability of new chromium(II) and chromium(III) heteroscorpionate complexes.

Kilpatrick AF, Kulangara SV, Cushion MG, Duchateau R, Mountford P.

Dalton Trans. 2010 Apr 21;39(15):3653-64. doi: 10.1039/b926333k. Epub 2010 Mar 5.

PMID:
20354618
36.

Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection.

Cushion MT, Linke MJ, Ashbaugh A, Sesterhenn T, Collins MS, Lynch K, Brubaker R, Walzer PD.

PLoS One. 2010 Jan 29;5(1):e8524. doi: 10.1371/journal.pone.0008524.

37.

Dicationic and zwitterionic catalysts for the amine-initiated, immortal ring-opening polymerisation of rac-lactide: facile synthesis of amine-terminated, highly heterotactic PLA.

Clark L, Cushion MG, Dyer HE, Schwarz AD, Duchateau R, Mountford P.

Chem Commun (Camb). 2010 Jan 14;46(2):273-5. doi: 10.1039/b919162c. Epub 2009 Nov 25.

PMID:
20024349
38.

Sequence and structure of the linear mitochondrial genome of Pneumocystis carinii.

Sesterhenn TM, Slaven BE, Keely SP, Smulian AG, Lang BF, Cushion MT.

Mol Genet Genomics. 2010 Jan;283(1):63-72. doi: 10.1007/s00438-009-0498-7. Epub 2009 Nov 17.

PMID:
19921262
39.

Functional characterization and localization of Pneumocystis carinii lanosterol synthase.

Joffrion TM, Collins MS, Sesterhenn T, Cushion MT.

Eukaryot Cell. 2010 Jan;9(1):107-15. doi: 10.1128/EC.00264-09. Epub 2009 Nov 6.

40.

Imidazoquines as antimalarial and antipneumocystis agents.

Vale N, Prudêncio M, Marques CA, Collins MS, Gut J, Nogueira F, Matos J, Rosenthal PJ, Cushion MT, do Rosário VE, Mota MM, Moreira R, Gomes P.

J Med Chem. 2009 Dec 10;52(23):7800-7. doi: 10.1021/jm900738c.

41.

Synthesis and SAR of alkanediamide-linked bisbenzamidines with anti-trypanosomal and anti-pneumocystis activity.

Huang TL, Vanden Eynde JJ, Mayence A, Collins MS, Cushion MT, Rattendi D, Londono I, Mazumder L, Bacchi CJ, Yarlett N.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5884-6. doi: 10.1016/j.bmcl.2009.08.073. Epub 2009 Aug 23.

42.

Preclinical drug discovery for new anti-pneumocystis compounds.

Cushion MT, Walzer PD.

Curr Med Chem. 2009;16(20):2514-30. Review.

PMID:
19601796
43.

Misinformation about Pneumocystis.

Brubaker R, Redhead SA, Stringer JR, Keely SP, Cushion MT.

Clin Exp Dermatol. 2009 Oct;34(7):e426-7. doi: 10.1111/j.1365-2230.2009.03411.x. Epub 2009 Jun 25. No abstract available.

PMID:
19558583
44.

Copper(I) complexes of cis,cis-1,3,5-tris(mesitylideneamino)cyclohexane ligands: synthesis, structure and substrate selectivity.

Cushion M, Ebrahimpour P, Haddow MF, Hallett AJ, Mansell SM, Orpen AG, Wass DF.

Dalton Trans. 2009 Mar 7;(9):1632-5. doi: 10.1039/b818827k. Epub 2009 Jan 21.

PMID:
19421608
45.

Pneumocystis workshop: 10th anniversary summary.

Beck JM, Cushion MT.

Eukaryot Cell. 2009 Apr;8(4):446-60. doi: 10.1128/EC.00309-08. Epub 2009 Jan 23. No abstract available.

46.

Sodium, magnesium and zinc complexes of mono(phenolate) heteroscorpionate ligands.

Schofield AD, Barros ML, Cushion MG, Schwarz AD, Mountford P.

Dalton Trans. 2009 Jan 7;(1):85-96. doi: 10.1039/b813116c. Epub 2008 Oct 21.

PMID:
19081975
47.

Synthesis, structures and reactivity of group 4 hydrazido complexes supported by calix[4]arene ligands.

Clulow AJ, Selby JD, Cushion MG, Schwarz AD, Mountford P.

Inorg Chem. 2008 Dec 15;47(24):12049-62. doi: 10.1021/ic801735c.

PMID:
18998672
48.

Phylogenomic analyses support the monophyly of Taphrinomycotina, including Schizosaccharomyces fission yeasts.

Liu Y, Leigh JW, Brinkmann H, Cushion MT, Rodriguez-Ezpeleta N, Philippe H, Lang BF.

Mol Biol Evol. 2009 Jan;26(1):27-34. doi: 10.1093/molbev/msn221. Epub 2008 Oct 14.

PMID:
18922765
49.

Biofilm formation by Pneumocystis spp.

Cushion MT, Collins MS, Linke MJ.

Eukaryot Cell. 2009 Feb;8(2):197-206. doi: 10.1128/EC.00202-08. Epub 2008 Sep 26.

50.

Novel bisbenzimidazoles with antileishmanial effectiveness.

Mayence A, Pietka A, Collins MS, Cushion MT, Tekwani BL, Huang TL, Vanden Eynde JJ.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2658-61. doi: 10.1016/j.bmcl.2008.03.020. Epub 2008 Mar 10.

PMID:
18367395

Supplemental Content

Loading ...
Support Center